SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors discuss the potential impact of a reported earnings miss, attributed to a tax dispute in Brazil, despite revenue being in line with expectations. Community members are debating whether this dip presents a buying opportunity or signals a larger correction for the streaming giant, with some questioning the company's valuation and future growth prospects in an increasingly competitive market.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is experiencing volatility as traders discuss the impact of a widespread AWS outage and its potential fallout, including possible lawsuits. The community is also weighing the implications of Anthropic choosing Google over Amazon for cloud computing needs, sparking debate about AWS's competitive positioning against $MSFT and $GOOGL. Despite these concerns, some investors view the dip as a buying opportunity, citing Amazon's strong market presence.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending due to a sector-wide selloff, sparking debates about potential manipulation and overbought conditions; the community is weighing whether this dip presents a buying opportunity, or signals further declines. Discussions also involve upcoming earnings and speculation around potential deals, particularly concerning AI data centers. Some traders are expressing concerns about dilution and the stock's correlation with Bitcoin's volatility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is experiencing a selloff, prompting discussions about potential manipulation and profit-taking after a significant run-up, with some community members pointing to broader sector weakness as a factor; despite the dip, bulls remain confident in the long-term prospects of IREN given its position in AI and data centers, while others express concerns over short-term volatility.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as investors discuss its AI strategy and potential partnerships, including rumored collaborations with Anthropic. Community talking points highlight Google's AI capabilities, such as Gemini, DeepMind, and GCP, emphasizing the company's potential to dominate the AI landscape. Broader discussions cover capital expenditures on data centers and a generally positive outlook on the stock's valuation relative to peers.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following its earnings report, with community chatter focused on procedure growth and the company's future outlook. While some express optimism about the robotic surgery market and potential for new all-time highs, others are concerned about margin pressures and valuation. Discussions also revolve around the impact of tariffs and expansion into international markets.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending following its earnings report and subsequent guidance, which has led to significant discussion about the company's near-term outlook. Community members are debating whether the stock is oversold, with some pointing to broader sector concerns and potential trade tensions affecting future performance. Others suggest the dip presents a buying opportunity, citing the company's long-term fundamentals and dividend.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors assess the potential impact of OpenAI's browser and Google's AI initiatives, including a significant investment in Indian infrastructure. Community discussions revolve around whether the stock's recent pullback represents a buying opportunity amidst the evolving AI landscape and competition in search.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as traders discuss a potential rotation from gold, spurred by a recent drop in gold prices, into BTC. Community members are debating short-term bearish signals versus long-term bullish sentiment, with some pointing to upcoming catalysts and others wary of market manipulation. Broader market factors, including comments from political figures like Trump and the Federal Reserve's stance on digital assets, are also influencing the conversation around Bitcoin's price action.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending after securing significant funding to advance its schizophrenia treatment, sparking enthusiastic discussion among investors. The community is focused on the potential for FDA approval and the stock's low float, while also debating the possibility of dilution and short squeezes. The stock's surge is being viewed in the context of the broader biotech sector and its potential for high-reward plays.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novartis (NVS) on Monday announced positive results from its late-stage trials evaluating its investigational drug Ianalumab in adults with active Sjögren's disease.Ianalumab is a novel fully human monoclonal antibody being investigated for its potential to treat various B-cell-driven autoimmune diseases. The drug’s mechanism of action targets B cells in two ways: combining B cell depletion and interruption of BAFF-R-mediated signals of B cell function and survival.Guggenheim said the positive updates give evidence that BAFF-signaling disruption and B cell depletion are "a valid approach" for hard-to-treat autoimmune diseases, which has a positive read-through for Zura Bio (ZURA). Shares of <a href="https://stocktwits.com/symbol/ZURA">Zura</a>, which Guggenheim deems "significantly undervalued," traded 3% higher at the time of writing.Novartis <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-patients-sjogrens-disease">said</a> that its two late-stage trials for Sjögren's disease met the primary endpoint of demonstrating statistically significant improvements in disease activity. Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_12_02_03_PM_png_fdf22daf95.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:02 p.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:02 p.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure>Sjögren’s disease is a systemic, chronic autoimmune disorder that causes inflammation and tissue damage, impacting the entire body. It primarily affects exocrine glands, leading to excessive dryness, with over 90% of patients experiencing dry eyes and dry mouth.“These Phase III studies mark a significant milestone. We look forward to engaging with health authorities to discuss these findings in the near future,” said Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis.Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease, the company said, while adding that it plans to submit the drug to health authorities globally.NYSE-listed shares of the company traded 1% higher at the time of writing.Ianalumab originated from Novartis’ early collaboration with MorphoSys AG, a company which it later acquired in 2024. In clinical trials, Ianalumab showed promising efficacy and a favorable safety profile in Sjögren’s disease, systemic lupus erythematosus, and immune thrombocytopenia.While NVS shares are up by 21% this year, ZURA is down 42%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/avantor-responds-to-activist-investor-engine-capital-letter/chru67IRde5">Avantor Responds To Activist Investor Engine Capital’s Letter: ‘Acting With Urgency To Strengthen Growth’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

Equity

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.


Zura Bio to Present at the Leerink Partners Global Healthcare Conference

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that...

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the...

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that...

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported...

Zura Bio to Present at Three Upcoming Investor Conferences in September

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its...

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that...

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the...

Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Zura Bio Ltd - Ordinary Shares - Class A

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.18	--	--	N/A
Q2 '25	-$0.19	-$0.17	9.73%	BEAT
Q1 '25	-$0.16	-$0.19	-19.82%	MISSED
Q4 '24	-$0.16	-$0.15	6.25%	BEAT
Q3 '24	-$0.13	-$0.26	-97.83%	MISSED

ZURA
Zura Bio Ltd - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ZURA News

ZURAZura Bio Ltd - Ordinary Shares - Class A